阿奇霉素治疗解脲支原体的疗效：系统评价和荟萃分析。

Efficacy of azithromycin in treating Ureaplasma urealyticum: a systematic review and meta-analysis.

机构信息

Department of Pharmacy, Changxing People's Hospital, Changxing, Zhejiang, China.

Key Laboratory of Intelligent Pharmacy and Individualized Therapy of Huzhou, Zhejiang, China.

出版信息

BMC Infect Dis. 2023 Mar 16;23(1):163. doi: 10.1186/s12879-023-08102-5.

DOI:10.1186/s12879-023-08102-5

PMID:36927441

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10021952/

Abstract

BACKGROUND

Ureaplasma urealyticum is the most prevalent genital mycoplasma isolated from the urogenital tract of females, but there is no unified treatment plan. This study aimed to evaluate the efficacy of azithromycin in treating Ureaplasma urealyticum.

METHODS

From the earliest to June 2022, published randomized controlled trials (RCTs) on azithromycin treatment of Ureaplasma urealyticum were retrieved by searching PubMed, Embase, Cochrane Library, and Web of Science. Two reviewers independently extracted the data. We utilized the Cochrane risk-of-bias assessment technique to assess the quality of included RCTs. The data were analyzed using the R language (version 4.0.4) software.

RESULTS

Seven RCTs were finally included, involving 512 participants (240 in the experimental group, 272 in the control group). The experimental group was treated with azithromycin monotherapy, while the control group was treated with doxycycline or a placebo. Meta-analysis results suggested that azithromycin has a comparable therapeutic effect on Ureaplasma urealyticum in comparison to that of controls (risk ratio [RR] = 1.03, 95% confidence interval [CI] 0.94-1.12). Subgroup analysis showed that the dose and duration of azithromycin may don't affect its efficacy.

CONCLUSION

Regarding the meta-analysis that we performed based on existing clinical studies, azithromycin is quite effective in treating Ureaplasma urealyticum.

摘要

背景

解脲支原体是从女性泌尿生殖道分离出来的最常见的生殖道支原体，但目前尚无统一的治疗方案。本研究旨在评估阿奇霉素治疗解脲支原体的疗效。

方法

检索 PubMed、Embase、Cochrane 图书馆和 Web of Science 数据库，检索时间从建库至 2022 年 6 月，收集阿奇霉素治疗解脲支原体的随机对照试验（RCT）。由 2 位评价者独立提取数据，采用 Cochrane 偏倚风险评估工具评价纳入 RCT 的质量，使用 R 语言（版本 4.0.4）软件进行数据分析。

结果

最终纳入 7 项 RCT，共 512 例患者（实验组 240 例，对照组 272 例）。实验组采用阿奇霉素单药治疗，对照组采用多西环素或安慰剂治疗。Meta 分析结果显示，阿奇霉素治疗解脲支原体的疗效与对照组相当（RR=1.03，95%CI 0.94-1.12）。亚组分析显示，阿奇霉素的剂量和疗程可能不会影响其疗效。